Tag: Hepatitis
Availability of Generic Antivirals for Hepatitis B Increasing
Drop in median price of WHO-prequalified generic tenofovir from $208 to $32 from 2004 to 2016
Universal Screening Best Strategy for Hepatitis C in France
Universal screening is cost-effective when treatment is initiated regardless of fibrosis stage
HCV-Infected Kidney Transplant More Efficient in HCV-Infected
Increases quality-adjusted life expectancy, reduces costs versus transplant of HCV-uninfected kidney
Direct-Acting Antivirals Effective for Hepatitis C in Seniors
Increased likelihood of adverse events, anemia secondary to ribavirin for those age 75 or older
Post-Transplant Tx Reduces Wait for Kidney in Hep C+ Patients
Delaying treatment until after transplant doesn't adversely impact kidney allograft or survival
Hepatitis C-Exposed Infants Not Adequately Screened
Low screening rate seen at same time as increase in hepatitis C virus prevalence among pregnant women
Novel Purchasing Strategy Could Cut Medicaid Costs for HCV Meds
Strategy involves making deal with manufacturer for a lump-sum payment in return for 100 percent rebate
Sofosbuvir Improves Renal Safety in Patients With Chronic Hep C
Patients with mild, moderate renal impairment showed improvement in renal biomarkers over one year
Metabolic Syndrome Common With Chronic Hep B Infection
Metabolic syndrome also associated with higher alanine aminotransferase levels longitudinally
Hepatitis C Screening Increasing Among Baby Boomers
Screening prevalence 11.5 to 12.8 percent; similar rate for cohort born from 1966 to 1985
